ScinoPharm Taiwan (stock code 1789) announced consolidated revenue of NT$3.264 billion for 2022, up 18% over the previous year, and net profit after tax of NT$353 million, up 45% over the previous year, with after-tax earnings per share of NT$0.45.

ScinoPharm’s pre-filled syringe and liquid injectable products, and lyophilized injectables passed the FDA’s pre-approval on-site inspections in March and October 2022.

ScinoPharm Taiwan, Ltd. (1789) and Nano Targeting & Therapy (NTT) initiated an agreement for a licensing mode technology transfer in December 2022 to establish a collaborative development plan based on a technology that utilizes mesoporous silica nanoparticle (MSN) to deliver docetaxel to treat brain cancer.

ScinoPharm Taiwan (stock code 1789) announced its consolidated revenue for 2020 of NTD 3.083 billion, after-tax net profit of NTD 282 million, and after-tax earnings per share of NTD 0.36. Faced with the highly uncertain global market last year and COVID-19, the company has maintained stable operations according to its original strategy.

ScinoPharm Taiwan (1789), an all-round niche pharmaceutical company, has been actively investing in business transformation and strengthening the internal integration of resources in recent years, and the results have gradually emerged.